Clinical and Practical Psychopharmacology
Posts about this type
Clinical and Practical Psychopharmacology
Epilepsy, Antiepileptic Drugs, and Adverse Pregnancy Outcomes, 2: Major Congenital Malformations
July 3, 2024
This article reviews evidence from a large registry, a population-based study, and a meta-analysis on the risks of major congenital malformation with untreated epilepsy and with exposure to antiepileptic...
Clinical and Practical Psychopharmacology
Epilepsy, Antiepileptic Drugs, and Adverse Pregnancy Outcomes, 1: Recent Research
June 5, 2024
This article provides women who have epilepsy and who use antiepileptic drugs during pregnancy with information about the many risks to which they and their fetus/neonate are exposed at...
Clinical and Practical Psychopharmacology
Diabetic medications and major congenital malformations
March 11, 2024
Diabetes is prevalent and poses risks to both mother and child during pregnancy. Evidence shows that diabetes is best treated during pregnancy, with insulin a first-line treatment and metformin...
Clinical and Practical Psychopharmacology
Physical Exercise and Health, 5: Sedentary Time as a Risk Factor for Adverse Physical and Mental Health Outcomes
January 29, 2024
Topics include why sedentariness is important, how it is defined and assessed, and why sedentary behaviors are common in daily life.
Clinical and Practical Psychopharmacology
Physical Exercise and Health, 4: A Guide to Understanding What to Do, How, and Why—Part 2
December 11, 2023
Subjects covered include how cardiorespiratory, muscle-strengthening, balancing, and other exercises benefit the heart, strengthen muscles and bones, improve balance, and reduce risk of falls and fractures. Guidance is provided...
Clinical and Practical Psychopharmacology
Physical Exercise and Health, 2: Benefits of Different Levels and Patterns of Activity
October 11, 2023
This article provides guidance about exercise for adults, including how many steps per day are enough, whether bursts of activity during the day improve health, and whether “weekend warrior”...
Clinical and Practical Psychopharmacology
Using Percentiles to Understand Standardized Mean Difference as a Measure of Effect Size
August 7, 2023
Chittaranjan Andrade, MD, explains the use of SMDs as a measure of effect size. A recent meta-analysis of the effect of ChEIs on hallucinations and delusions in Alzheimer and...
Clinical and Practical Psychopharmacology
ChEIs for Delusions and Hallucinations in Alzheimer Disease and Parkinson Disease: Significant Benefits?
July 31, 2023
Chittaranjan Andrade, MD, takes a closer look at a recent meta-analysis indicating that donepezil, rivastigmine, and galantamine lessened both delusions and hallucinations in Alzheimer disease and Parkinson disease.
Clinical and Practical Psychopharmacology
Gestational Exposure to Benzodiazepines and Z-Hypnotics and Risk of Adverse Pregnancy Outcomes
April 3, 2023
Chittaranjan Andrade, MD, discusses recent studies on exposure to benzodiazepines and hypnotics and risk of major congenital malformation and other adverse pregnancy outcomes.
Clinical and Practical Psychopharmacology
Prolactin, Antipsychotics, and Fracture Risk
January 30, 2023
Fracture risk associated with antipsychotics may be related to whether they increase prolactin. If long-term treatment with prolactin-raising agents is necessary, prolactin levels should be regularly monitored.
Clinical and Practical Psychopharmacology
How to Critically Read a Study of Adverse Outcomes With Antidepressant Use
December 7, 2022
Chittaranjan Andrade, MD, explains how to think critically about a study covered in the media. Concepts include confounding by indication, regression, and how to deal with confounding.
